Israeli personalized cancer therapy company OncoHost, announced on Tuesday that it raised $35 million in a Series C funding round to finance its multicenter PROPHETIC trial that tests the company’s machine-learning-based host response profiling platform PROphet, a precision oncology diagnostic solution.  The funding will also be used to support the company’s commercial launch, which is […]

OncoHost's platform combines proteomic analysis with AI to predict host responses to immunotherapy, and gain insight into cancer treatments.

This is the Israeli AI imaging company's 6th FDA clearance for an automated solution that helps identify at-risk patients and helps radiologists with workflow.

Founded in 2017, Nucleai developed a platform that leverages tissue datasets to produce insights into cancer biology, increase clinical trial efficacy and improve patient care.

The program will be piloted within Sheba's Oncology Department and will be offered to several hundred patients.